Phenobarbital: Updated safety information following targeted signal management
Final EU-language translations of the recommended product information changes for phenobarbital-containing veterinary medicines have been published following targeted signal management.
Background
On 13 November 2026, the EMA published the final translations of product information text resulting from the targeted signal management procedure for phenobarbital. The assessment was conducted within veterinary pharmacovigilance with the involvement of the CMDv. The procedure ran from April 2024 to May 2026.
Safety assessment
The procedure reviewed reports including anticonvulsant hypersensitivity syndrome in dogs and cats and pancreatitis, elevated serum lipids and elevated liver enzymes in dogs. The CMDv concluded that the benefit–risk balance of phenobarbital-containing veterinary medicines remains unchanged, while recommending changes to marketing authorisations to adequately describe the risks in dogs.
Product information changes
The published translations address special warnings, adverse events and interactions, including information on liver parameters and serum lipids, pancreatitis risk and concomitant use with potassium bromide. The precise wording and monitoring intervals should be checked against the official product information applicable to each medicine.
Regulatory interpretation
Publication of final translations does not by itself establish that every national marketing authorisation has already been updated. Product-specific implementation obligations and timelines must be checked with the relevant competent authority. This is neither a new indication nor a general amendment to Regulation (EU) 2019/6.
Practical implications
Marketing authorisation holders should assess product scope, approved product information, necessary variations and national implementation. Pharmacovigilance and medical information processes should reflect the approved safety wording consistently. Veterinarians should consult the current product information for the specific medicine used.
Official primary sources
EMA: Final translations of product information text (13 November 2026)
